177Lu-PSMA治疗转移性睾丸混合生殖细胞肿瘤
本文报道一例46岁男性转移性睾丸混合生殖细胞肿瘤患者,经反复手术和治疗后仍进展。68Ga-PSMA PET/CT显示转移灶强烈摄取PSMA,遂给予177Lu-PSMA治疗以控制疾病,但α-甲胎蛋白水平进展,68Ga-PSMA PET/CT显示混合治疗反应。
要点
- PSMA在多种肿瘤中可过表达,PSMA靶向放射性核素治疗或可用于PSMA高摄取的非前列腺癌恶性肿瘤。
- 本例转移性睾丸混合生殖细胞肿瘤患者经68Ga-PSMA PET/CT评估后接受177Lu-PSMA治疗。
- 治疗后α-甲胎蛋白水平进展,68Ga-PSMA PET/CT显示混合治疗反应。
核心结论
- 177Lu-PSMA治疗用于PSMA高摄取的转移性睾丸混合生殖细胞肿瘤患者后,α-甲胎蛋白水平进展,68Ga-PSMA PET/CT显示混合治疗反应。
研究设计与样本
- 个案报道,1例46岁男性转移性睾丸混合生殖细胞肿瘤患者,经反复手术和治疗后仍进展。
主要发现
- 68Ga-PSMA PET/CT显示转移灶强烈摄取PSMA。
- 给予177Lu-PSMA治疗以控制疾病后,α-甲胎蛋白水平进展。
- 治疗后68Ga-PSMA PET/CT检测到混合治疗反应。
临床怎么用
- 对PSMA高摄取的恶性肿瘤,可考虑行68Ga-PSMA PET/CT评估177Lu-PSMA治疗资格。
局限性
- 本文为单例个案报道,结果不能推广至所有转移性睾丸混合生殖细胞肿瘤患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) overexpression in various tumors are demonstrated in both in vitro and in vivo studies. Prostate-specific membrane antigen-directed radionuclide therapies are generally used in prostate cancer and could be also useful in PSMA-avid other malignancies. Herein, we present a case of a 46-year-old male patient who had progressive metastatic testicular mixed germ cell tumor, despite repeated operations and treatments. 68Ga-PSMA PET/CT was performed to assess eligibility for 177Lu-PSMA therapy. Patient had intense PSMA uptake in metastatic lesions, and 177Lu-PSMA has been given to control of disease. However, α-fetoprotein level progressed, and mixed therapy response was detected in 68Ga-PSMA PET/CT.
引用
- Has Simsek D, Civan C, Ekenel M, et al. 177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor. Clin Nucl Med. 2021. PMID: 33630811. doi:10.1097/RLU.0000000000003563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。